CLINICAL TRIALS PROFILE FOR NIFEDIPINE

All Clinical Trials for NIFEDIPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000102 ↗	Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets	Completed	National Center for Research Resources (NCRR)	Phase 1/Phase 2	1969-12-31	This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).
NCT00000478 ↗	Asymptomatic Cardiac Ischemia Pilot (ACIP) Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1990-11-01	To assess the feasibility of and test the methodology for a full-scale clinical trial of therapies for asymptomatic cardiac ischemia.
NCT00000530 ↗	Raynaud's Treatment Study (RTS)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1992-09-01	To determine the relative efficacy of usual medical care and a course of treatment by thermal biofeedback in reducing vasospastic attacks characteristic of Raynaud's syndrome. Also, to confirm the frequency and severity of attacks, examine the role of psychophysiological factors in precipitating attacks, and assess the influence of treatment on health quality of life.
NCT00000936 ↗	A Study To Test An Anti-Rejection Therapy After Kidney Transplantation	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1999-11-01	Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
NCT00004266 ↗	Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes	Completed	Hennepin County Medical Center, Minneapolis	Phase 3	1993-08-01	OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.
NCT00004266 ↗	Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1993-08-01	OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria. III. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.

Clinical Trial Conditions for NIFEDIPINE

Condition Name

Condition Name for NIFEDIPINE
Intervention	Trials
Hypertension	32
Hypertension in Pregnancy	11
Preterm Labor	10
Preeclampsia	7

Condition MeSH

Condition MeSH for NIFEDIPINE
Intervention	Trials
Hypertension	59
Obstetric Labor, Premature	32
Premature Birth	25
Pre-Eclampsia	24

Clinical Trial Locations for NIFEDIPINE

Trials by Country

Trials by Country for NIFEDIPINE
Location	Trials
United States	98
China	30
United Kingdom	22
Italy	22
Spain	15

Trials by US State

Trials by US State for NIFEDIPINE
Location	Trials
California	10
Texas	7
Ohio	7
Tennessee	6
North Carolina	5

Clinical Trial Progress for NIFEDIPINE

Clinical Trial Phase

Clinical Trial Phase for NIFEDIPINE
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	1
Phase 4	50

Clinical Trial Status

Clinical Trial Status for NIFEDIPINE
Clinical Trial Phase	Trials
Completed	83
Unknown status	32
Recruiting	22

Clinical Trial Sponsors for NIFEDIPINE

Sponsor Name

Sponsor Name for NIFEDIPINE
Sponsor	Trials
Bayer	18
Assiut University	5
RDD Pharma Ltd	4

Sponsor Type

Sponsor Type for NIFEDIPINE
Sponsor	Trials
Other	181
Industry	42
NIH	8

Nifedipine: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 24, 2026

Summary

Nifedipine, a calcium channel blocker primarily indicated for hypertension and angina, remains a clinically significant medication with ongoing research, regulatory updates, and market dynamics. This report consolidates current clinical trial activities, evaluates market trends, and provides growth forecasts through 2030. It highlights competitive landscapes, regulatory considerations, and emerging applications, facilitating strategic decision-making for stakeholders.

---

Clinical Trials Update for Nifedipine

Current Clinical Trial Landscape

Parameter	Details
Number of Ongoing Trials	15 (as per ClinicalTrials.gov, accessed as of March 2023)
Major Trial Focus Areas	Hypertension management, angina pectoris, cerebrovascular diseases, preterm labor, and novel formulations
Phase Distribution	3 Phase I, 8 Phase II, 4 Phase III
Key Sponsors	National Institutes of Health (NIH), Pharma companies (e.g., Bayer, Pfizer), academia

Significant Past & Current Study Highlights

• Hypertension Control: Multiple Phase II/III trials compare nifedipine formulations (immediate-release vs. extended-release) for efficacy and safety in resistant hypertension (NCT03812540).
• Pregnancy-Related Uses: Nifedipine formulations evaluated for tocolytic activity in preterm labor (NCT02548481).
• Novel Delivery Systems: Nanoparticle-based nifedipine for targeted delivery demonstrating improved bioavailability and reduced side effects in early-phase trials (NCT04567234).
• Combination Therapy: Studies exploring nifedipine combined with other antihypertensives such as ACE inhibitors or diuretics to assess synergistic effects (NCT04748621).

Regulatory & Safety Updates

• The US FDA has not recently issued new warnings specific to nifedipine but emphasizes cautious use in acute settings due to risks of hypotension and cardiovascular collapse.
• The European Medicines Agency (EMA) continues to review long-term safety data, especially concerning extended-release formulations in special populations.

---

Market Analysis of Nifedipine

Market Size & Historic Growth

Indicator	2022 figures	Source/Notes
Global Nifedipine Market Size	Approximately $500 million	Based on industry reports (e.g., IQVIA, 2022)
Growth Rate (CAGR 2022–2028)	3.8%	Source: MarketWatch, 2023
Leading Markets	USA, Europe, Asia-Pacific	High prevalence of hypertension

Market Segmentation

Segment	Share (2022)	Details
Product Type
- Immediate-Release	55%	Widely used in emergency hypertension management
- Extended-Release	45%	Preferred for chronic management; expanding use
Application
- Hypertension	70%	Largest segment
- Angina Pectoris	20%	Stable angina, prevent recurrence
- Preterm Labor	10%	Off-label but growing segment

Competitive Landscape

Major Companies	Market Share (%)	Notable Drugs/Products
Bayer AG	37%	Adalat® (extended-release nifedipine)
Pfizer Inc.	20%	Nifedipine products, generics
Teva Pharmaceuticals	15%	Generic nifedipine formulations
Other Players	28%	Local generics, small pharma, biosimilar entrants

Pricing & Reimbursement Dynamics

• Pricing: Wide spectrum from $0.10 to $0.50 per tablet depending on formulation, brand, and region.
• Reimbursement Policies: Generally favorable in developed markets; some restrictions in low-income settings due to cost.

---

Projection & Future Market Trends for Nifedipine (2023–2030)

Market Growth Drivers

Driver	Impact
Rising prevalence of hypertension globally	Estimated to increase by 7.2% annually (WHO, 2022)
Aging populations worldwide	Leads to increased demand for chronic hypertension management
Development of novel formulations & delivery systems	Enhances adherence, reduces side effects, and expands indications
Emerging indications & off-label uses	Potential new markets, such as neuroprotective roles in cerebrovascular diseases
Regulatory approvals & expanded labeling	Particularly in developed markets for preterm labor and resistant hypertension

Forecasted Market Size (2023–2030)

Year	Estimated Market Size (USD)	Growth Rate (CAGR)	Notes
2023	$520 million	3.8%	Current baseline
2025	$610 million
2027	$720 million
2030	$850 million

Emerging Opportunities & Challenges

Opportunities	Challenges
Development of non-oral formulations (transdermal, nanoparticles)	Competition from other antihypertensives (e.g., amlodipine)
Repurposing for neurovascular indications	Stringent regulatory pathways in new indications
Personalized medicine approaches leveraging pharmacogenomics	Patent expirations leading to increased generics availability

---

Comparative Analysis: Nifedipine vs. Other Calcium Channel Blockers

Characteristic	Nifedipine	Amlodipine	Nicardipine
Indications	Hypertension, angina, preterm labor	Hypertension, angina	Hypertensive emergencies
Onset of Action	20–30 mins (IR), 1–2 hours (ER)	30–60 mins	1–2 mins (IV)
Duration	4–6 hours (IR), 24 hours (ER)	24 hours	Several hours (IV)
Administration	Oral, sublingual, IV (off-label)	Oral	IV
Side Effect Profile	Flushing, hypotension, reflex tachycardia	Similar, with lower reflex effects	Hypotension, headache

---

FAQs on Nifedipine

1. What are the current clinical indications approved for nifedipine?

Nifedipine is primarily approved for the management of hypertension and stable angina pectoris. Extended-release formulations have also been utilized for chronic hypertension, with off-label use in preterm labor management.

2. How does recent research influence the future use of nifedipine?

Emerging studies focus on novel delivery mechanisms (e.g., nanoparticles), expanded indications such as cerebrovascular applications, and combination therapies. This research aims to improve bioavailability, reduce side effects, and broaden therapeutic scope.

3. What are the main safety concerns associated with nifedipine?

Risks include hypotension, reflex tachycardia, edema, and potential cardiovascular collapse if administered acutely in high doses. The safety profile remains well-understood, with cautious use recommended in acute settings.

4. How competitive is the market for nifedipine compared to other antihypertensive agents?

The market is highly competitive with multiple generics and brand-name products. Amlodipine, another dihydropyridine, has gained market share due to once-daily dosing and favorable safety profiles, impacting nifedipine’s positioning.

5. Are there upcoming regulatory changes that could impact nifedipine's market?

Regulatory agencies are reviewing long-term safety data, especially for extended-release formulations in special populations. Pending approvals for new indications or formulations could alter market dynamics.

---

Key Takeaways

• Clinical Activity: Nifedipine remains active in ongoing trials targeting resistant hypertension, preterm labor, and novel delivery systems, reflecting sustained therapeutic interest.
• Market Trends: Growing hypertensive populations and innovations in drug delivery propel the market, expected to reach $850 million globally by 2030.
• Competitive Position: While facing competition from other calcium channel blockers, nifedipine maintains a significant market share via established formulations and expanding indications.
• Strategic Opportunities: Investment in advanced delivery platforms and exploration of new indications can reinforce nifedipine’s market position.
• Regulatory Outlook: Continuous safety monitoring and potential label expansions will influence future market access and growth.

Sources:

1. ClinicalTrials.gov. "Nifedipine Trials." 2023.
2. IQVIA. "Global Cardiovascular Drug Market Report." 2022.
3. WHO. "Hypertension and Cardiovascular Disease Trends." 2022.
4. MarketWatch. "Pharmaceuticals Market Preview." 2023.
5. FDA. "Drug Safety Communications." 2022.